Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII

H. Gelhorn, E. Merikle, S. Krishnan, L. Nemes, C. Leissinger, L. Valentino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to determine physicians' preferences for medication attributes in the prophylactic treatment of this patient population. Haematologists from Europe (EU) and the United States (US) participated in a discrete choice exercise to explore their preferences for medication attributes (efficacy, cost, scientific evidence, dosing frequency and administration time) associated with prophylaxis for severe haemophilia A in patients with inhibitors to factor VIII. Physicians' preferences for medication attributes were assessed through completion of 25 trade-off tasks that included a choice between two hypothetical medications each comprised of one randomized level of each medication attribute. Participants also completed a sociodemographic questionnaire. Data were analysed using a random effects logit model. Participants (N = 36: US = 19; EU = 17) were 80.6% men, had a mean of 19.8 years (SD ± 8.1) [range 6-35] of practice experience. The physicians treated an average of 5.7 (±5.5) patients with severe haemophilia A and inhibitors per month and reported treating 36.2% of these patients prophylactically. The most important medication attributes for prophylactic treatment were efficacy [Relative Importance (RI) = 35.0%] and scientific evidence (RI = 34.1%), whereas treatment cost (12.0%), dosing frequency (10.8%) and administration time (8.2%) were less important. Results were similar across the EU and US. Efficacy and scientific evidence are the primary considerations for physicians' choice of prophylactic medications for use in this patient population.

Original languageEnglish
Pages (from-to)119-125
Number of pages7
JournalHaemophilia
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Factor VIII
Hemophilia A
Physicians
Therapeutics
Health Care Costs
Population
Logistic Models
Exercise
Costs and Cost Analysis

Keywords

  • Discrete choice
  • Efficacy
  • Haemophilia A
  • Patients with inhibitors
  • Physician preference
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII. / Gelhorn, H.; Merikle, E.; Krishnan, S.; Nemes, L.; Leissinger, C.; Valentino, L.

In: Haemophilia, Vol. 19, No. 1, 01.2013, p. 119-125.

Research output: Contribution to journalArticle

Gelhorn, H. ; Merikle, E. ; Krishnan, S. ; Nemes, L. ; Leissinger, C. ; Valentino, L. / Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII. In: Haemophilia. 2013 ; Vol. 19, No. 1. pp. 119-125.
@article{0fb26e350e1e4ce2afdcbdeb4d9b8f05,
title = "Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII",
abstract = "Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to determine physicians' preferences for medication attributes in the prophylactic treatment of this patient population. Haematologists from Europe (EU) and the United States (US) participated in a discrete choice exercise to explore their preferences for medication attributes (efficacy, cost, scientific evidence, dosing frequency and administration time) associated with prophylaxis for severe haemophilia A in patients with inhibitors to factor VIII. Physicians' preferences for medication attributes were assessed through completion of 25 trade-off tasks that included a choice between two hypothetical medications each comprised of one randomized level of each medication attribute. Participants also completed a sociodemographic questionnaire. Data were analysed using a random effects logit model. Participants (N = 36: US = 19; EU = 17) were 80.6{\%} men, had a mean of 19.8 years (SD ± 8.1) [range 6-35] of practice experience. The physicians treated an average of 5.7 (±5.5) patients with severe haemophilia A and inhibitors per month and reported treating 36.2{\%} of these patients prophylactically. The most important medication attributes for prophylactic treatment were efficacy [Relative Importance (RI) = 35.0{\%}] and scientific evidence (RI = 34.1{\%}), whereas treatment cost (12.0{\%}), dosing frequency (10.8{\%}) and administration time (8.2{\%}) were less important. Results were similar across the EU and US. Efficacy and scientific evidence are the primary considerations for physicians' choice of prophylactic medications for use in this patient population.",
keywords = "Discrete choice, Efficacy, Haemophilia A, Patients with inhibitors, Physician preference, Prophylaxis",
author = "H. Gelhorn and E. Merikle and S. Krishnan and L. Nemes and C. Leissinger and L. Valentino",
year = "2013",
month = "1",
doi = "10.1111/hae.12011",
language = "English",
volume = "19",
pages = "119--125",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII

AU - Gelhorn, H.

AU - Merikle, E.

AU - Krishnan, S.

AU - Nemes, L.

AU - Leissinger, C.

AU - Valentino, L.

PY - 2013/1

Y1 - 2013/1

N2 - Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to determine physicians' preferences for medication attributes in the prophylactic treatment of this patient population. Haematologists from Europe (EU) and the United States (US) participated in a discrete choice exercise to explore their preferences for medication attributes (efficacy, cost, scientific evidence, dosing frequency and administration time) associated with prophylaxis for severe haemophilia A in patients with inhibitors to factor VIII. Physicians' preferences for medication attributes were assessed through completion of 25 trade-off tasks that included a choice between two hypothetical medications each comprised of one randomized level of each medication attribute. Participants also completed a sociodemographic questionnaire. Data were analysed using a random effects logit model. Participants (N = 36: US = 19; EU = 17) were 80.6% men, had a mean of 19.8 years (SD ± 8.1) [range 6-35] of practice experience. The physicians treated an average of 5.7 (±5.5) patients with severe haemophilia A and inhibitors per month and reported treating 36.2% of these patients prophylactically. The most important medication attributes for prophylactic treatment were efficacy [Relative Importance (RI) = 35.0%] and scientific evidence (RI = 34.1%), whereas treatment cost (12.0%), dosing frequency (10.8%) and administration time (8.2%) were less important. Results were similar across the EU and US. Efficacy and scientific evidence are the primary considerations for physicians' choice of prophylactic medications for use in this patient population.

AB - Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to determine physicians' preferences for medication attributes in the prophylactic treatment of this patient population. Haematologists from Europe (EU) and the United States (US) participated in a discrete choice exercise to explore their preferences for medication attributes (efficacy, cost, scientific evidence, dosing frequency and administration time) associated with prophylaxis for severe haemophilia A in patients with inhibitors to factor VIII. Physicians' preferences for medication attributes were assessed through completion of 25 trade-off tasks that included a choice between two hypothetical medications each comprised of one randomized level of each medication attribute. Participants also completed a sociodemographic questionnaire. Data were analysed using a random effects logit model. Participants (N = 36: US = 19; EU = 17) were 80.6% men, had a mean of 19.8 years (SD ± 8.1) [range 6-35] of practice experience. The physicians treated an average of 5.7 (±5.5) patients with severe haemophilia A and inhibitors per month and reported treating 36.2% of these patients prophylactically. The most important medication attributes for prophylactic treatment were efficacy [Relative Importance (RI) = 35.0%] and scientific evidence (RI = 34.1%), whereas treatment cost (12.0%), dosing frequency (10.8%) and administration time (8.2%) were less important. Results were similar across the EU and US. Efficacy and scientific evidence are the primary considerations for physicians' choice of prophylactic medications for use in this patient population.

KW - Discrete choice

KW - Efficacy

KW - Haemophilia A

KW - Patients with inhibitors

KW - Physician preference

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84871013022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871013022&partnerID=8YFLogxK

U2 - 10.1111/hae.12011

DO - 10.1111/hae.12011

M3 - Article

C2 - 23005041

AN - SCOPUS:84871013022

VL - 19

SP - 119

EP - 125

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 1

ER -